Evidence map›Paper›PMID 24752661›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2014

Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H.

John Lynes, Mia Wibowo, Carl Koschmann, Gregory J Baker, Vandana Saxena, A K M G Muhammad, Niyati Bondale, Julia Klein, Hikmat Assi, Andrew P Lieberman and 2 more

Open access · greenAbstract read
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Lentiviral-Induced Spinal Cord Gliomas in Rat Model.International journal of molecular sciences · 2021
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

John LynesDepartment of Neurosurgery, University of Michigan, School of Medicine, 4570 MSRB II, 1150 West Medical Center Drive, Ann Arbor, MI, 48109, USA.
Mia Wibowo
Carl Koschmann
Gregory J Baker
Vandana Saxena
A K M G Muhammad
Niyati Bondale
Julia Klein
Hikmat Assi
Andrew P Lieberman
Maria G Castro
Pedro R Lowenstein
Regional West Medical Center · USUniversity of Michigan–Ann Arbor · US

Funding

Training Program in Molecular HematologyT32HL007622 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SUNG WON CHOI, Jordan A. Shavit · 1986 to 2026
$9.2M
Gutless Adenovirus Mediated Gene Therapy for GliomaU01NS052465 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2007 to 2011
$3.1M
Engineering the Brain Immune System for Tumor TherapyR01NS057711 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2009 to 2013
$2.0M
Crosstalk between glioma cells & immune cells in the tumor microenvironment: TherR01NS074387 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2011 to 2015
$1.9M
Brain immune responses:Cellular & Molecular MechanismsR01NS061107 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2008 to 2012
$1.7M
Mechanisms of glioma growth and invasion novel therapeutic strategiesR01NS082311 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2013 to 2017
$1.7M
Gene Therapy and the Brain: Neuroimmune InteractionsR01NS054193 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2007 to 2011
$1.6M
NHLBI NIH HHS T32 HL007622NINDS NIH HHS 1R01-NS 054193NINDS NIH HHS 1R01-NS 057711NINDS NIH HHS 1R01-NS 061107NINDS NIH HHS 1R01-NS074387NINDS NIH HHS 1R01-NS082311NINDS NIH HHS 1UO1-NS052465NINDS NIH HHS R01 NS054193NINDS NIH HHS R01 NS057711NINDS NIH HHS R01 NS061107NINDS NIH HHS R01 NS074387NINDS NIH HHS R01 NS082311NINDS NIH HHS U01 NS052465
6 · The paper itself

Abstract

In human gliomas, the RTK/RAS/PI(3)K signaling pathway is nearly always altered. We present a model of experimental gliomagenesis that elucidates the contributions of genes involved in this pathway (PDGF-B ligand, HRAS-G12V, and AKT). We also examine the effect on gliomagenesis by the potential modifier gene, IDH1-R132H. Injections of lentiviral-encoded oncogenes induce de novo gliomas of varying penetrance, tumor progression, and histological grade depending on the specific oncogenes used. Our model mimics hallmark histological structures of high-grade glioma, such as pseudopalisades, glomeruloid microvascular proliferation, and diffuse tumor invasion. We use our model of gliomagenesis to test the efficacy of an experimental brain tumor gene therapy. Our model allowed us to test the contributions of oncogenes in the RTK/RAS/PI(3)K pathway, and their potential modification by over-expression of mutated IDH1, in glioma development and progression in rats. Our model constitutes a clinically relevant system to study gliomagenesis, the effects of modifier genes, and the efficacy of experimental therapeutics.

Indexed as

AnimalsBrain NeoplasmsDisease Models, AnimalGenetic TherapyGliomaHumansIsocitrate DehydrogenaseLentivirusMutationProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-sisProto-Oncogene Proteins p21(ras)RatsRats, Sprague-DawleySignal TransductionSurvival AnalysisHRAS protein, humanIDH1 protein, humanIsocitrate DehydrogenaseProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-sisProto-Oncogene Proteins p21(ras)

Identifiers

PMID24752661
PMCPMC4121445
OpenAlexW2035147119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.